

Lifevantage Corp  
Form 8-K  
October 12, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 12, 2012

**Lifevantage Corporation**

(Exact name of registrant as specified in its charter)

Colorado  
(State or other Jurisdiction  
of Incorporation)

001-35647  
(Commission  
File Number)

90-0224471  
(IRS Employer  
Identification No.)

Edgar Filing: Lifevantage Corp - Form 8-K

9815 S. Monroe Street, Suite 100, Sandy, UT

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (801) 432-9000

84070

(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 12, 2012, Lifevantage Corporation (the Company) issued a press release announcing its appointment of Darlene R. Walley, Ph.D. as its new Chief Science Officer effective October 22, 2012. Dr. Walley will replace Dr. Joe McCord who is stepping down from his position as Chief Science Officer effective October 22, 2012 in order to focus exclusively on the Company's efforts to champion third-party peer reviewed studies of the Company's flagship product, Protandim, and to educate the Company's independent distributors on the advancement of Nrf2 science.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	Press release issued by the Company on October 12, 2012.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: October 12, 2012

**Lifevantage Corporation**

By: /s/ Rob Cutler  
Rob Cutler  
General Counsel